Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Chem Pharm Bull (Tokyo) ; 68(1): 91-95, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31902904

RESUMEN

Magnolia Flower is a crude drug used for the treatment of headaches, toothaches, and nasal congestion. Here, we focused on Magnolia kobus, one of the botanical origins of Magnolia Flower, and collected the flower parts at different growth stages to compare chemical compositions and investigate potential inhibitory activities against interleukin-2 (IL-2) production in murine splenic T cells. After determining the structures, we examined the inhibitory effects of the constituents of the bud, the medicinal part of the crude drug, against IL-2 production. We first extracted the flower parts of M. kobus from the bud to fallen bloom stages and analysed the chemical compositions to identify the constituents characteristic to the buds. We found that the inhibitory activity of the buds against IL-2 production was more potent than that of the blooms. We isolated two known compounds, tiliroside (1) and syringin (2), characteristic to the buds from the methanol (MeOH) extract of Magnolia Flower. Moreover, we examined the inhibitory activities of both compounds against IL-2 production and found that tiliroside (1) but not syringin (2), showed strong inhibitory activity against IL-2 production and inhibited its mRNA expression. Thus, our strategy to examine the relationship between chemical compositions and biological activities during plant maturation could not only contribute to the scientific evaluation of medicinal parts of crude drugs but also assist in identifying biologically active constituents that have not yet been reported.


Asunto(s)
Interleucina-2/metabolismo , Magnolia/química , Extractos Vegetales/química , Animales , Línea Celular , Flavonoides/química , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Flores/química , Flores/metabolismo , Glucósidos/química , Glucósidos/aislamiento & purificación , Glucósidos/farmacología , Interleucina-2/genética , Magnolia/metabolismo , Ratones , Fenilpropionatos/química , Fenilpropionatos/aislamiento & purificación , Fenilpropionatos/farmacología , Linfocitos T/citología , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo
2.
Immunol Lett ; 167(2): 116-24, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26277554

RESUMEN

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a key glycolytic enzyme that is predominantly localized in the cytoplasm. However, recent studies have suggested that GAPDH is released by various cells and that extracellular GAPDH is involved in the regulation of neuritogenesis in neuronal cells. It has also been reported that GAPDH is expressed on the surfaces of macrophages and functions as a transferrin receptor. However, since GAPDH is a leaderless protein the mechanisms by which it reaches the extracellular environment remain unclear. Here, we examined the role of P2X7 receptor (P2X7R), an ATP-gated cation channel, in the unconventional release of GAPDH from microglial cells, the resident macrophages in the brain. The activation of P2X7R by ATP triggered GAPDH release from lipopolysaccharide (LPS)-primed microglial cells. ATP-induced microvesicle formation, exosome release, and K(+) efflux followed by caspase-1 activation are likely involved in the GAPDH release, but ATP-induced dilatation of membrane pores and lysosome exocytosis are not. It was also demonstrated that exogenous GAPDH facilitated LPS-induced phosphorylation of p38 MAP kinase in microglial cells. These findings suggest that P2X7R plays an important role in the unconventional release of GAPDH from microglial cells, and the GAPDH released into the extracellular space might be involved in the regulation of the neuroinflammatory response in the brain.


Asunto(s)
Adenosina Trifosfato/metabolismo , Gliceraldehído-3-Fosfato Deshidrogenasas/metabolismo , Microglía/inmunología , Microglía/metabolismo , Caspasa 1/metabolismo , Células Cultivadas , Activación Enzimática , Ensayo de Inmunoadsorción Enzimática , Exocitosis/inmunología , Espacio Extracelular , Humanos , Inmunohistoquímica , Lipopolisacáridos/inmunología , Lisosomas/inmunología , Lisosomas/metabolismo , Fosforilación , Potasio/metabolismo , Cultivo Primario de Células , Receptores Purinérgicos P2X7/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
3.
J Neurochem ; 117(4): 712-23, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21395581

RESUMEN

The potent pro-inflammatory cytokine, interleukin-1ß (IL-1ß), is synthesized as an inactive 33-kDa precursor (pro-IL-1ß) and is processed by caspase 1 into the bioactive 17-kDa mature form. The P2X7 receptor, an ATP-gated cation channel, plays an essential role in caspase 1 activation, production and release of mature bioactive 17-kDa form. We recently reported ATP induces the release of an unconventional 20-kDa form of IL-1ß (p20-IL-1ß) from lipopolysaccharide-primed microglial cells. Emerging evidence suggests physiological relevance for p20-IL-1ß; however, the underlying mechanisms for its production and release remain unknown. Here, we investigated the pathways involved in the ATP-induced production of p20-IL-1ß using lipopolysaccharide-primed mouse microglial cells. The activation of P2X7 receptor by ATP triggered p20-IL-1ß production under acidic extracellular conditions. ATP-induced p20-IL-1ß production was blocked by pepstatin A, a potent inhibitor of the lysosomal protease, cathepsin D. The removal of extracellular Ca(2+) inhibited the p20-IL-1ß production as well as ATP-induced cathepsin D release via lysosome exocytosis. The acidic extracellular pH also facilitated the dilatation of membrane pore after ATP stimulation. Since facilitation of pore dilatation results in cytolysis accompanied with cytoplasmic pro-IL-1ß leakage, our data suggest the leaked pro-IL-1ß is processed into p20-IL-1ß by cathepsin D released after ATP stimulation under acidic extracellular conditions.


Asunto(s)
Catepsina D/farmacología , Espacio Extracelular/metabolismo , Interleucina-1beta/biosíntesis , Lipopolisacáridos/farmacología , Microglía/metabolismo , Receptores Purinérgicos P2X7/efectos de los fármacos , Adenosina Trifosfato/farmacología , Animales , Western Blotting , Caspasa 1/metabolismo , Línea Celular , Exocitosis/efectos de los fármacos , Concentración de Iones de Hidrógeno , Inmunohistoquímica , Lisosomas/efectos de los fármacos , Lisosomas/metabolismo , Ratones , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Proteínas del Tejido Nervioso/biosíntesis , Pepstatinas/farmacología
4.
J Radiat Res ; 49(4): 381-9, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18413978

RESUMEN

We previously reported attenuation of autoimmune disease by low-dose gamma-ray irradiation in MRL-lpr/lpr mice. Here, we studied the effect of low-dose gamma-ray irradiation on collagen-induced arthritis (CIA) in DBA/1J mice. Mice were immunized with type II collagen, and exposed to low-dose gamma-rays (0.5 Gy per week for 5 weeks). Paw swelling, redness, and bone degradation were suppressed by irradiation, which also delayed the onset of pathological change and reduced the severity of the arthritis. Production of tumor necrosis factor-alpha, interferon-gamma, and interleukin-6, which play important roles in the onset of CIA, was suppressed by the irradiation. The level of anti-type II collagen antibody, which is essential for the onset of CIA, was also lower in irradiated CIA mice. The population of plasma cells was increased in CIA mice, but irradiation blocked this increase. Since regulatory T cells are known to be involved in suppression of autoimmune disease, the population of CD4(+)CD25(+)Foxp3(+) regulatory T cells was measured. Intriguingly, a significant increase of these regulatory T cells was found in irradiated CIA mice. Overall, our data suggest that low-dose gamma-ray irradiation could attenuate CIA through suppression of pro-inflammatory cytokines and autoantibody production, and induction of regulatory T cells.


Asunto(s)
Artritis/metabolismo , Artritis/radioterapia , Citocinas/metabolismo , Rayos gamma/uso terapéutico , Animales , Artritis/inducido químicamente , Artritis/patología , Colágeno Tipo II , Relación Dosis-Respuesta en la Radiación , Masculino , Ratones , Ratones Endogámicos DBA , Dosificación Radioterapéutica , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA